232 related articles for article (PubMed ID: 30009467)
1. In vivo quantification of glial activation in minipigs overexpressing human α-synuclein.
Lillethorup TP; Glud AN; Landeck N; Alstrup AKO; Jakobsen S; Vang K; Doudet DJ; Brooks DJ; Kirik D; Hinz R; Sørensen JC; Landau AM
Synapse; 2018 Dec; 72(12):e22060. PubMed ID: 30009467
[TBL] [Abstract][Full Text] [Related]
2. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
3. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
5. Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs.
Lillethorup TP; Glud AN; Alstrup AKO; Mikkelsen TW; Nielsen EH; Zaer H; Doudet DJ; Brooks DJ; Sørensen JCH; Orlowski D; Landau AM
Exp Neurol; 2018 May; 303():142-152. PubMed ID: 29428213
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
7. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
8. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
[TBL] [Abstract][Full Text] [Related]
9. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats.
Thomsen MB; Ferreira SA; Schacht AC; Jacobsen J; Simonsen M; Betzer C; Jensen PH; Brooks DJ; Landau AM; Romero-Ramos M
Neurobiol Dis; 2021 Feb; 149():105229. PubMed ID: 33352233
[TBL] [Abstract][Full Text] [Related]
10. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
11. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
[TBL] [Abstract][Full Text] [Related]
12. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
13. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
[TBL] [Abstract][Full Text] [Related]
14. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
15. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
[TBL] [Abstract][Full Text] [Related]
16. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
17. Voltage-dependent anion channel involved in the α-synuclein-induced dopaminergic neuron toxicity in rats.
Lu L; Zhang C; Cai Q; Lu Q; Duan C; Zhu Y; Yang H
Acta Biochim Biophys Sin (Shanghai); 2013 Mar; 45(3):170-8. PubMed ID: 23291291
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
19. AAV2/DJ-mediated alpha-synuclein overexpression in the rat substantia nigra as early stage model of Parkinson's disease.
von Hövel FF; Rumpel R; Ratzka A; Schreiner D; Grothe C
Cell Tissue Res; 2019 Oct; 378(1):1-14. PubMed ID: 30989398
[TBL] [Abstract][Full Text] [Related]
20. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
